Medical Industry Feature

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Yi Bin Chen, MD Guest: Olaf Penack, MD For the past several decades, standard treatment for acute graft-versus-host disease (aGVHD) has been systemic high-dose steroids.1 While essential in some ways to initially control aGVHD, steroids are not beneficial in the long run due to the immunosuppression and toxicities associated with high cumulative doses.1,2 So what can be done moving forward to improve first-line steroid response and minimize cumulative steroid exposure? Joining Dr Charles Turck to discuss the potential of nonimmunosuppressive steroid-sparing agents for the first-line treatment of aGVHD are Drs Yi Bin Chen and Olaf Penack. Dr Chen is the Director of the Hematopoietic Cell Transplant and Cell Therapy Program at Massachusetts General Hospital, and Dr Penack is a senior physician and principal investigator within Hematology and Oncology at Charité Berlin. References: Bell EJ, Yu J, Bhatt V, et al. Healthcare resource utilization an

Guest: Kathleen M. Buchheit, MD Guest: Joseph K. Han, MD Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with a low quality of life and increased healthcare utilization,1,2 and patients often continue to have severe symptoms despite therapy.​3 Understanding the role of underlying inflammatory pathways and epithelial dysfunction may help inform clinical decision making for these patients.​3,4 In this program, Dr Kathleen Buchheit and Dr Joseph Han share their insights on the pathophysiology of CRSwNP and how unaddressed underlying inflammation may contribute to a variety of challenges for patients. Dr Buchheit is an Assistant Professor of Medicine at Harvard Medical School, specializing in Allergy and Immunology. Dr Han is a Professor of Otolaryngology, the Chief for the Division of Rhinology and Endoscopic Sinus and Skull Base Surgery, and the Chief of the Division of Allergy at Eastern Virginia Medical School in Norfolk, Virginia. References: Mullol J, et al. J Allergy Clin Im

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Miguel-Angel Perales, MD Guest: Anna Sureda, MD, PhD Unfortunately, the treatment paradigm for acute graft-versus-host disease (aGVHD) has not changed for a couple of decades as steroids remain the first-line treatment.1 However, steroids are not a targeted therapy, and they have many side effects that are not well tolerated by patients, including life-threatening infections.1-3 Given these risks, it is important to know how to manage infections related to immunosuppression and optimize the care of patients with aGVHD. Joining Dr Charles Turck to discuss the current landscape of aGVHD management are Dr Miguel-Angel Perales and Dr Anna Sureda. Dr Miguel-Angel Perales is the Chief of the Adult Bone Marrow Transplantation Service at Memorial Sloan Kettering Cancer Center in New York, and Dr Sureda is the Head of Clinical Hematology at the University of Barcelona in Spain. References: Bell EJ, Yu J, Bhatt V, et al. Healthcare resource utilization

Guest: Donald Kohan, MD, PhD Increased formation of renal endothelin one is associated with renal injury.1 In several studies, activation of the ETA receptor has been shown to contribute to IgA nephropathy (IgAN) progression, and markers of endothelin system activity are elevated in patients with the disease.2,3-5 Join Dr Donald Kohan as he dives into the latest research on this connection, which could provide insight into new tailored therapy approaches for IgAN patients. Dr Kohan is a nephrologist at University of Utah Health in Salt Lake City. References: Kohan DE, Barton M. Kidney Int. 2014;86(5):896-904. doi:10.1038/ki.2014.143 Kohan DE et al. Kid Int Rep. 2023;8(11):2198-2210. doi:10.1016/j.ekir.2023.07.023 Lehrke I et al. J Am Soc Nephrol. 2001;12:2321-2329. doi.org/10.1681/ASN.v12112321 Zanatta CM et al. Ren Fail. 2012;34(3):308-315. doi:10.3109/0886022X.2011.647301 Tycova I et al. Physiol Res. 2018;67:93-105. doi.org/10.33549/physiolres.933670 FA-11319389 12/24

Complement 3 glomerulopathy (C3G) is an ultra-rare kidney disease characterized by overactivation of the alternative complement pathway. This program provides insights into the pathogenesis of the disease. FA-11319389 12/24

In this brief video, learn more about growing evidence supporting the key role of airway epithelium dysfunction in driving inflammation in CRSwNP. ©2025 Amgen and AstraZeneca. All rights reserved.US-94728 Last Updated 1/25

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Stephen I. Pelton, MD In the last two pre-pandemic flu seasons, approximately half of hospitalizations from influenza in the US were in adults 65 and older.1,2 A recent real-world study evaluated the relative effectiveness of adjuvanted influenza vaccine versus high-dose vaccine in preventing test-confirmed influenza hospitalizations in this age group across three flu seasons between 2017 and 2020.3 Dr. Charles Turck sits down with Dr. Stephen Pelton, an author on this study, to explore the findings and their implications for influenza vaccination strategies in older adults. Dr. Pelton is a Professor of Pediatrics at the Boston University Chobanian and Avedisian School of Medicine. References: Pelton SI, Nguyen VH, Mould-Quevedo JF. The value of influenza vaccination in the older adult population. A stochastic model estimation of the benefit of vaccination to prevent the severe outcomes in the U.S. Poster presented at: IDWeek 2023; October 11-15;

Host: Jennifer Caudle, DO Guest: Lori Guyton, MD Guest: Douglas Scharre, MD As our understanding of Alzheimer’s disease continues to evolve, it’s critical to understand the clinical and pathologic changes underpinning Alzheimer’s disease as it may be able to help guide early diagnosis and clinically meaningful management decisions.1 That’s why Drs. Douglas Scharre and Lori Guyton speak with Dr. Jennifer Caudle about Alzheimer’s disease pathophysiology and how it translates to clinical practice. Dr. Scharre is a Professor of Clinical Neurology and Psychiatry as well as the Director for the Division of Cognitive Neurology at the Ohio State University Wexner Medical Center in Columbus, and Dr. Guyton is a practicing neurologist with Neurology of Southern Illinois in Herrin. Reference: Porsteinsson A, Isaacson R, Knox S, Sabbagh M, Rubino I. Diagnosis of early Alzheimer’s disease: Clinical practice in 2021. J Prev Alzheimers Dis. 2021;8:371-386. © Eisai Inc. 2024. All Rights Reserved.AD-M2130

Host: Jennifer Caudle, DO Guest: Lori Guyton, MD Guest: Douglas Scharre, MD Our understanding of the mechanisms underlying Alzheimer’s disease is growing, and these advances can help inform diagnosis and management strategies. In fact, as our understanding of Alzheimer’s disease evolves, our strategies to diagnose and manage the disease are changing to focus on early diagnosis and intervention.1 Joining Dr. Jennifer Caudle to discuss our current understanding of disease progression as well as the impact and benefit of diagnosing Alzheimer’s disease early are Drs. Douglas Scharre and Lori Guyton. Dr. Scharre is the Director of the Division of Cognitive Neurology at the Ohio State University Wexner Medical Center in Columbus, and Dr. Guyton is a practicing neurologist with Neurology of Southern Illinois in Herrin. Reference: Atri A. The Alzheimer’s disease clinical spectrum: Diagnosis and management. Med Clin North Am. 2019;103:263-293. © Eisai Inc. 2024. All Rights Reserved.AD-M2123 Novemb

Host: Jennifer Caudle, DO Guest: Virginia Kaklamani, MD Guest: Anne O'Dea, MD When caring for patients with ER-positive/HER2-negative metastatic breast cancer, there’s uncertainty on the optimal second-line sequencing of treatments after disease progression on first-line CDK4/6 inhibition and endocrine therapy. But the findings from the EMERALD trial, which led to the approval of ORSERDU® (elacestrant) for patients with ER-positive/HER2-negative ESR1-mutated metastatic breast cancer after disease progression on endocrine therapy,1 contribute to our understanding of second-line treatment options. Dive into the results from the EMERALD trial and subgroup analysis with Drs. Virginia Kaklamani and Anne O'Dea. Dr. Kaklamani is a Professor of Medicine in the Division of Hematology and Medical Oncology at the UT Health Sciences Center in San Antonio, and Dr. O'Dea is a breast medical oncologist at the University of Kansas Cancer Center.

Guest: Scott Gottlieb, MD Host: Charles Turck, PharmD, BCPS, BCCCP Patients 50+ with moderate-to-severe plaque psoriasis face adherence challenges, increased risk of comorbidities, and insurance transitions from commercial to Medicare. To learn more about how ILUMYA® (tildrakizumab-asmn) helps address the specific treatment needs of these patients, join Dr. Charles Turck as he speaks with Dr. Scott Gottlieb, a physician at Schweiger Dermatology Group in Exton, Pennsylvania.

Unknown: Arnold Advincula, MD With over 20 years of experience performing the transabdominal cerclage, Dr. Arnold Advincula, Chief of Gynecologic Specialty Surgery at NewYork-Presbyterian and Columbia, has a deep expertise in helping women with cervical insufficiency achieve successful pregnancies. Through the expanded use of robotics, Dr. Advincula and his team are completing the procedure minimally invasively and with more accuracy and precision. Watch to learn how this advanced technique is transforming gynecologic surgery by reducing recovery time and helping women reach their reproductive goals. © 2024 NewYork-Presbyterian

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Shizuko Morimoto, PsyD Digital therapeutics are a rapidly developing type of treatment option across several therapeutic areas, including mental health. And while the technology is advancing rapidly, the science behind it needs time to catch up, so it’s important to evaluate the supporting evidence when considering digital therapeutics for mental health.1 Joining Dr. Charles Turck to share her insights on how we can assess digital therapeutics is Dr. Sarah Shizuko Morimoto, Associate Professor of Population Health Sciences at the University of Utah in Salt Lake City. Reference: American Psychiatric Association. Accessed July 3, 2024. https://www.psychiatry.org/psychiatrists/practice/mental-health-apps/the-app-evaluation-model Dr. Morimoto is a paid consultant of Otsuka. November 2024 US.UNB.X.24.00100

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Steven Maron, MD, MSc Given the recent identification of actionable biomarkers like PD-L1 and MSI-H,1-3 it’s important to test patients with gastroesophageal cancer for these biomarkers as they may provide insights into options for a patient’s treatment plan.4,5 To learn more about how we can detect biomarkers and other key considerations for biomarker screening in gastroesophageal cancer, Dr. Charles Turck speaks with Dr. Steven Maron, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York. References: The Cancer Genome Atlas Network. Nature. 2014;513:202-209. Fontana E, et al. Ther Adv Med Oncol. 2016;8:113-125. Yang B, et al. J Exp Clin Cancer Res. 2019;38:283. American Cancer Society. https://www.fightcancer.org/sites/default/files/Improving%20Access%20to%20Biomarker%20Testing_FINAL.pdf. Accessed July 20, 2024. Catenacci DVT, et al. Future Oncol. 2019;15:2073-2082. ©2024 Amgen Inc. All rights reserved. USA-OCF-824

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Robert McCarron, MD Guest: Arwen Podesta, MD Digital therapeutics are a relatively new and intriguing treatment option in mental health care but translating them from a clinical trial to clinical practice can be challenging. That’s why Drs. Robert McCarron and Arwen Podesta join Dr. Charles Turck to share strategies for incorporating digital therapeutics into clinical practice. Dr. McCarron is a Professor in the Department of Psychiatry and Human Behavior at the University of California, Irvine School of Medicine, and Dr. Podesta is the President of the Louisiana Psychiatric Medical Association. Drs. McCarron and Podesta are consultants for Otsuka. September 2024 US.UNB.X.24.00073

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Maggie Emerson, DNP, APRN, PMHNP-BC Guiding patients and caregivers through the fast-moving landscape of digital therapeutics can be a challenging but worthwhile part of providing effective and accessible care. That’s why Dr. Charles Turck speaks with Dr. Maggie Emerson about partnering with patients and caregivers around this relatively new treatment in mental health care. Dr. Emerson is a Clinical Associate Professor at the University of Nebraska Medical Center College of Nursing in Omaha. Dr. Emerson is a paid consultant of Otsuka. September 2024 US.UNB.X.24.00082

Host: Matt Birnholz, MD Guest: Jennifer L. Payne, MD Guest: Melissa Simon, MD Postpartum depression is a serious medical condition that is among the most common complications during and after pregnancy; however, it is often underdiagnosed.1-4 To learn more about screening patients for postpartum depression, Dr. Matt Birnholz speaks with Dr. Jennifer Payne and Dr. Melissa Simon about screening strategies, the impact of health inequities, and the latest medical guidelines regarding the importance of early screening for postpartum depression. Dr. Payne is a Professor of Psychiatry and Neurobehavioral Sciences as well as Obstetrics and Gynecology at the University of Virginia, and Dr. Simon is a Professor of Obstetrics and Gynecology at the Northwestern University Feinberg School of Medicine. References American Psychiatric Association. Depressive disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. 5th ed. American Psychiatric Publish

Guest: Jennifer L. Payne, MD Guest: Melissa Simon, MD Since postpartum depression is a serious medical condition that can negatively impact mothers, infants, and partners, it is important to identify symptoms in a timely manner.1-4 Dr. Jennifer Payne and Dr. Melissa Simon are here to share their clinical experiences screening patients for postpartum depression, explore strategies to overcome common challenges in screening, and identify best practices for collaborating in the care of perinatal women. Dr. Payne is a Professor of Psychiatry and Neurobehavioral Sciences as well as Obstetrics and Gynecology at the University of Virginia, and Dr. Simon is a Professor of Obstetrics and Gynecology at the Northwestern University Feinberg School of Medicine. References American Psychiatric Association. Depressive disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. 5th ed. American Psychiatric Publishing; 2013:155-188. Campbell SB, Cohn JF, Meye

Guest: TJ Gan, MD, MBA, MHS, FRCA (UK), FRCA (lre), LicAc Guest: Dru Riddle, PhD, DNP, CRNA When it comes to postoperative nausea and vomiting (PONV) management, multimodal, antiemetic therapy based on patients’ risk factors is routinely provided to minimize the incidence, but unfortunately, patients may still develop breakthrough PONV, in which an antiemetic should be administered from a different class from what's given for prevention.1 Barhemsys® (amisulpride) is an FDA-approved antiemetic for the treatment of PONV in patients who have or have not received prophylaxis.2 Learn more about this treatment option along with current management guidelines, key clinical considerations, and a real-world case study with TJ Gan, MD, MBA, MHS, and Dru Riddle, PhD, DNP. Dr. Gan is the Head of the Division of Anesthesiology and Perioperative Medicine, Critical Care, and Pain Medicine at the University of Texas MD Anderson Cancer Center in Houston, and Dr. Riddle is a certified nurse anesthetist at Texas Ch

Host: Jennifer Caudle, DO Guest: Tamera A. Paczos, MD, FACOG, FACP The utility of p16 and Ki-67 immunostaining in biopsies has helped lead to the development of dual staining in cytology specimens. So what do clinicians need to know about the dual stain cytology test? Take a deep dive into this topic as Dr. Jennifer Caudle is joined by Dr. Tamera A. Paczos, Vice President, Associate Chief Medical Officer with BioReference Laboratories. COBAS and CINTEC are trademarks of Roche.All other product names and trademarks are the property of their respective owners. 02/23